Clinical Trial

Sickle Cell Hemoglobinopathies and Bone Health

Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated March 27, 2025 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
This research study has two purposes. The first purpose is to determine whether having sickle cell trait (SCT) is a risk factor for the development of bone thinning at an earlier age than expected. Nearly 10% of African Americans (AA) carry sickle cell trait and most of them are unaware of it. African Americans are less likely to develop thin bones than whites, but if they sustain a bone fracture, they are more likely to die from it. We believe having sickle cell trait may lead to bone thinning and predispose a subset of African Americans to dangerously thin bones. The second purpose is to try to understand why individuals with sickle cell disease (SCD) have thinner bones than healthy individuals do. Doctors have already discovered that people with sickle cell disease have very thin bones, but they have not determined why. Our study will try to identify whether the bone thinning is from the body not making enough bone or from the body losing bone once it is made.
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2014-12-01; most recent amendment 2025-03-24.
Status change: Recruiting → Active, Not Recruiting 2022-11-01
Trial Details
NCT Number NCT02306993
Lead Sponsor UConn Health
Conditions Sickle Cell Disease, Sickle Cell Trait
Enrollment 45 participants
Start Date 2014-05
Primary Completion 2025-12 (estimated)
Study Completion 2025-12 (estimated)
Updated on ClinicalTrials.gov 2025-03-27